Clindamycin/adapalene/benzoyl peroxide, sold under the brand name Cabtreo, is a fixed-dose combination medication used for the treatment of acne. It contains clindamycin 1.2%, as the phosphate, a lincosamide antibacterial; adapalene 0.15%, a synthetic retinoid; and benzoyl peroxide 3.1%, an oxidizing agent. It is applied to the skin.
Clindamycin/adapalene/benzoyl peroxide was approved for medical use in the United States in October 2023. It is the first triple-combination topical acne treatment approved by the US Food and Drug Administration.
References